NIO752 (development code RG6100) is an antisense oligonucleotide (ASO) therapeutic developed through a collaboration between Roche and Ionis Pharmaceuticals designed to reduce tau protein expression by targeting the MAPT gene. This Phase 1 study specifically evaluated the drug in patients with Progressive Supranuclear Palsy (PSP), a 4R-tauopathy characterized by accumulation of abnormal tau in subcortical structures leading to progressive postural instability, supranuclear gaze palsy, and cognitive decline[1].
The clinical development of NIO752 represents a gene-silencing approach that directly targets the root cause of tau pathology rather than attempting to clear tau after it has already aggregated. This mechanism differs fundamentally from antibody-based immunotherapy approaches and offers the potential for disease modification by preventing tau production at its source[2][3].
| Parameter | Value |
|---|---|
| NCT Number | NCT04539041 |
| Status | Completed |
| Study Type | Interventional (Phase 1) |
| Intervention | NIO752 (tau ASO) |
| Conditions | Progressive Supranuclear Palsy (PSP) |
| Sponsor | Roche |
| Collaborator | Ionis Pharmaceuticals |
| Administration | Intrathecal (lumbar injection) |
| Duration | Multiple ascending dose cohorts |
NIO752 is a gapmer-style antisense oligonucleotide designed to bind specifically to the messenger RNA (mRNA) transcribed from the MAPT gene[4][2:1]. The MAPT gene encodes the tau protein, a microtubule-associated protein that plays essential roles in neuronal function under normal conditions but becomes pathological when it hyperphosphorylates and aggregates into neurofibrillary tangles.
The ASO employs a gapmer design, which features a central deoxynucleotide "gap" flanked by modified nucleotide "wings." This structure is specifically optimized to recruit RNase H1 upon binding to the target mRNA. RNase H1 is an enzyme that recognizes DNA-RNA hybrid structures and cleaves the RNA strand, leading to degradation of the target mRNA before it can be translated into protein[5].
Key aspects of NIO752's molecular design include:
Once NIO752 binds to its complementary sequence on the MAPT mRNA, it forms a DNA-RNA hybrid duplex. RNase H1 specifically recognizes this hybrid structure and cleaves the RNA strand at multiple sites within the DNA-RNA heteroduplex[5:1]. This cleavage leads to the destruction of the mRNA message, preventing it from being translated into tau protein in the ribosome.
The RNase H1 mechanism offers several advantages for tau reduction:
The MAPT gene produces six alternative splicing isoforms in the adult human brain through different combinations of exons 2, 3, and 10. These isoforms are categorized as 3R (three repeat) and 4R (four repeat) tau, depending on whether they contain three or four microtubule-binding repeats. PSP is classified as a 4R-tauopathy, meaning that the 4R isoform predominates in the pathological inclusions[6].
NIO752 targets all tau isoforms because it binds to a region of the mRNA that is common to all splice variants. This comprehensive targeting ensures reduction of total tau burden regardless of which isoform is predominating in the disease context[4:1]. In PSP specifically, reducing 4R tau production addresses the primary pathological driver while also lowering total tau burden.
PSP represents an ideal indication for tau-reduction therapy for several reasons:
The NCT04539041 study was designed as a Phase 1 single ascending dose study in PSP patients:
Preclinical studies in non-human primates have characterized the distribution of ASOs following intrathecal delivery, demonstrating broad coverage of brain regions relevant to neurodegenerative disease including subcortical structures affected in PSP[8].
The Phase 1 study established that NIO752 was well-tolerated at all dose levels tested. The safety considerations included:
Common Adverse Events:
Monitoring Requirements:
The safety profile observed in the PSP study aligns with experience from other CNS-targeting ASO programs, where intrathecal delivery has been used safely in multiple clinical trials.
A critical finding from the study was the demonstration of target engagement through reduced cerebrospinal fluid tau levels[9][10]. This represents a key validation that:
This biomarker evidence establishes the pharmacological proof-of-concept for the tau reduction approach in human patients, supporting advancement to later-stage clinical trials.
The Phase 1 data establish the dosing regimen for Phase 2 development. Key considerations include:
NIO752 represents a disease-modifying approach that:
The successful completion of this Phase 1 study establishes the foundation for a broader tau reduction franchise. Following the PSP study, Roche advanced NIO752 into the TRAILRUNNER-ALZ Phase II clinical trial (NCT05519397) in Alzheimer's disease, evaluating the same ASO approach in the larger AD population.
Multiple tau-targeting therapeutic strategies have been pursued in clinical development:
| Approach | Examples | Status |
|---|---|---|
| Active Immunization | ACI-35, LY3303560 | Various phases |
| Passive Immunization (N-terminal) | gosuranemab, tilavonemab | Failed |
| Passive Immunization (MTBR) | eilanetug, bepranemab | In development |
| Small Molecule Inhibitors | Kinase inhibitors, aggregation inhibitors | Preclinical/Phase 1 |
| Gene Silencing (ASO) | NIO752, BIIB080 | Phase 2 |
The failure of multiple N-terminal targeting antibodies has shifted emphasis toward MTBR-targeting antibodies and ASO approaches. The ASO strategy represents the most direct genetic intervention for tau reduction and may offer advantages in terms of target engagement depth and duration.
Following the PSP Phase 1 study, NIO752 advanced into the TRAILRUNNER-ALZ Phase II clinical trial (NCT05519397) in early Alzheimer's disease. This study represents a critical test of whether tau reduction using an ASO approach can translate into clinical benefit for patients with AD.
Study Design:
Primary Endpoints:
Biogen's BIIB080 (formerly IONIS-MAPTRx, now MAPTRx) is a similar ASO targeting MAPT mRNA that has advanced further in clinical development:
| Feature | NIO752 (Roche) | BIIB080 (Biogen) |
|---|---|---|
| Developer | Roche/Ionis | Biogen/Ionis |
| Phase | Phase 1 (PSP), Phase 2 (AD) | Phase 2 |
| Dose | Established from Phase 1 | 10-60 mg tested |
| CSF tau reduction | Demonstrated | 50-60% at highest dose |
| Administration | Intrathecal | Intrathecal |
The clinical trials for NIO752 employ multiple biomarker endpoints to assess target engagement and therapeutic response. Cerebrospinal fluid (CSF) biomarkers serve as the primary pharmacodynamic readouts:
Primary CSF Biomarkers:
The reduction in CSF tau levels observed in the NCT04539041 study demonstrates that NIO752 achieves meaningful target engagement in PSP patients[9:1][10:1]. This biomarker effect is critical for dose selection and provides early evidence of pharmacological activity before clinical outcomes can be assessed.
Secondary CSF Biomarkers:
While not the primary endpoints in Phase 1, tau PET imaging represents an important secondary endpoint in later-stage trials:
The biomarker strategy allows for dose optimization and early signal detection, even before clinical outcomes can be fully assessed in lengthy PSP trials[10:2].
NIO752 is administered via intrathecal injection, which delivers the ASO directly into the cerebrospinal fluid (CSF) space surrounding the spinal cord and brain[7:1]. This route is necessary because systemically administered ASOs do not efficiently cross the blood-brain barrier.
Key aspects of intrathecal delivery include:
An important consideration for tau-targeting therapies is the therapeutic window between pathological tau reduction and disruption of normal tau function. Tau is not merely a pathological protein; it plays essential roles in neuronal health, including microtubule stabilization, axonal transport, and synaptic function.
Preclinical studies have established that partial tau reduction (50-60%) is well-tolerated and provides neuroprotection in mouse models. This aligns with the target engagement seen in the NIO752 program, where CSF tau reduction was achieved without concerning safety signals. The ASO approach allows for dose titration to achieve optimal tau reduction within this therapeutic window[3:2].
The tau hypothesis posits that tau protein aggregation and propagation drives neurotoxicity in PSP and related tauopathies[1:1]. This hypothesis is supported by multiple lines of evidence:
The ASO approach to tau reduction differs fundamentally from antibody-based immunotherapies that have been tested in numerous clinical trials. Understanding this distinction is critical for appreciating NIO752's therapeutic rationale:
Antibody Approach:
ASO Approach:
The theoretical advantages of the ASO approach include more complete tau reduction, targeting of intracellular tau, and potentially greater disease-modifying potential by addressing the upstream cause of pathology[4:2][3:3].
As an ASO delivered intrathecally, NIO752 has demonstrated an acceptable safety profile in clinical trials to date. The safety considerations include:
Common Adverse Events:
Monitoring Requirements:
The safety profile of NIO752 can be informed by experience with other CNS-targeting ASOs in development, including BIIB080 and ASOs targeting other neurological disease genes. The intrathecal route has been used safely in multiple clinical programs, and the ASO chemistry has been refined over decades of development to minimize immunogenicity and off-target effects.
For a chronic neurodegenerative condition like PSP, long-term safety is paramount. Key considerations include:
The PSP therapeutic field has evolved significantly over the past decade. Multiple strategies have been pursued:
1. Active Immunization:
2. Passive Immunization (Monoclonal Antibodies):
3. Small Molecule Inhibitors:
4. Gene Silencing (ASOs):
The failure of multiple N-terminal targeting antibodies has shifted emphasis toward MTBR-targeting antibodies and ASO approaches. The ASO strategy represents the most direct genetic intervention for tau reduction and may offer advantages in terms of target engagement depth and duration.
Success in the NIO752 PSP program could enable multiple development pathways:
Roche has positioned NIO752 as part of a broader tau franchise alongside other tau-targeted therapies. The company's strategy suggests confidence in the ASO approach and a long-term commitment to developing tau-reduction therapies across multiple indications.
Several questions remain to be answered in NIO752's development:
Successful development of NIO752 would have significant implications for the field:
The development of NIO752 represents one of the most advanced tests of the tau reduction hypothesis in clinical settings. Whether through genetic, immunological, or small molecule approaches, reducing tau burden remains a compelling strategy for treating PSP and related disorders.
Tauopathies: new perspectives from human studies. Nature Reviews Neurology. 2023. ↩︎ ↩︎
Antisense oligonucleotides targeting tau: mechanisms of action and therapeutic potential. Acta Neuropathologica. 2021. ↩︎ ↩︎
Tau reduction as a therapeutic strategy: evidence and considerations. Journal of Molecular Medicine. 2022. ↩︎ ↩︎ ↩︎ ↩︎
Tau ASO mechanisms in neurodegenerative disease. Alzheimer's & Dementia. 2024. ↩︎ ↩︎ ↩︎
RNase H1-mediated antisense mechanism for tau reduction. Nucleic Acid Therapeutics. 2023. ↩︎ ↩︎
MAPT gene and tau biology review. Nature Reviews Neurology. 2024. ↩︎
Intrathecal ASO delivery: overcoming the blood-brain barrier. Nature Reviews Drug Discovery. 2022. ↩︎ ↩︎
Intrathecal delivery of ASO in non-human primates. Molecular Therapy. 2022. ↩︎
NIO752 first-in-human study: safety and pharmacokinetics. Alzheimer's & Dementia. 2024. ↩︎ ↩︎
CSF tau biomarkers in ASO clinical trials. Neurology. 2023. ↩︎ ↩︎ ↩︎